QQ客服 官方微博 反馈留言

	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
	Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan
	2012
卷号	13期号:5页码:528-538
ISSN号	1470-2045
DOI	10.1016/S1470-2045(12)70087-6
URL标识	查看原文
收录类别	SCIE ; ESI高被引论文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6720738
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Miller, Vincent A.,Hirsh, Vera,Cadranel, Jacques,et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial[J],2012,13(5):528-538.
APA	Miller, Vincent A..,Hirsh, Vera.,Cadranel, Jacques.,Chen, Yuh-Min.,Park, Keunchil.,...&Yang, James Chih-Hsin.(2012).Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.,13(5),528-538.
MLA	Miller, Vincent A.,et al."Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial".13.5(2012):528-538.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。